We read with great interest the article by Winner et al1 in the Archives. This is the first study on sumatriptan and dihydroergotamine, both administered subcutaneously. One previous study,2 published in abstract form, reported on subcutaneous sumatriptan and low-dose intranasal dihydroergotamine and did not allow any reliable conclusion regarding comparison of the 2 drugs. Moreover, since sumatriptan costs more than dihydroergotamine, others3 have recently raised the question of whether the advantages of sumatriptan could offset this price difference.
The results of the study by Winner et al confirm the clinical impression that subcutaneous sumatriptan and dihydroergotamine are equally effective in aborting migraine attacks, although sumatriptan showed a speedier effect than dihydroergotamine, which in turn got a longer-lasting effect (probably because of its longer half-life). Previous studies reported that subcutaneous sumatriptan produces significant relief of headache at 10 minutes after treatment compared with placebo, with 50% of patients
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Neurology editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.